Feed ELOX
EL

Eloxx Pharmaceuticals, Inc.

ELOX · NASDAQ

$15.51 -1.27% (-$0.20)
1M -4.08%
Analiză

Un raport AI despre afacere, finanțe, evaluare, sentiment, știri și riscuri - scris în câteva minute.

Piotroski F-Score Weak
3/9
Valuation
-
N/A
P/FCF N/A
P/E N/A
EV/FFO N/A
Growth
-
N/A
FCF growth N/A
EPS growth N/A
Book val. growth N/A
Profitability
-
N/A
Op. margin N/A
Gross margin N/A
FCF margin N/A
Quality
-
N/A
ROA N/A
ROIC N/A
Asset turnover N/A
Debt
-
N/A
Debt/Assets N/A
Debt/Equity N/A
Net debt/EBITDA N/A
Stability
44 /100
Moderate
Profitable years 0
Beta -9.95x
EPS volatility 34.31%

Bulios Scoring descrie calitatea și istoricul unei companii, nu randamentul viitor. Un scor ridicat nu este un semnal de cumpărare. Află mai multe

Întreabă StockBot despre ELOX
Online

Despre companie

Eloxx Pharmaceuticals, Inc. (ELOX) is a biotechnology company specializing in the development of therapeutic therapies for genetic diseases and rare conditions. The company focuses on developing drug products that can correct genetic mutations and provide treatment for patients suffering from genetic disorders. Eloxx Pharmaceuticals targets the treatment of rare diseases such as cystic fibrosis, Duchenne muscular dystrophy, and other genetic disorders. With the growing awareness of the need for genetic disease treatment, Eloxx Pharmaceuticals, Inc. has the potential for sustained growth. Eloxx Pharmaceuticals, Inc. (ELOX) shares might be an interesting choice for investors seeking involvement in the biotechnology and therapeutic therapies for genetic diseases.

Nu este încă disponibil în limba dumneavoastră, așa că textul este în engleză.

Sector

Healthcare

Industry

Biotechnology

CEO

Sumit Aggarwal

Employees

10

Headquarters

Watertown

Evenimente viitoare

11 NOV.

Earnings

Upcoming earnings report

37d

Folosim cookie-uri esențiale pentru funcționarea site-ului și cookie-uri analitice opționale pentru a măsura utilizarea. Consultați Politica de confidențialitate.